Combination Therapy with Ezetimibe: An Alternative Strategy to Statin
Monotherapy in the Management of Patients with Non-cardiac Vascular
Disease

Kosmas   I.   Paraskevas; Jasjit   S.   Suri; Luca      Saba; Dimitri   P.   Mikhailidis

[1]
Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial. Lancet  2022; 400(10349): 380-90.
 [http://dx.doi.org/10.1016/S0140-6736(22)00916-3] [PMID: 35863366]

[2]
Abushamat LA, Ballantyne CM. Lowering LDL cholesterol in clinical practice: Time for change? Lancet  2022; 400(10349): 341-3.
 [http://dx.doi.org/10.1016/S0140-6736(22)01352-6] [PMID: 35863368]

[3]
Paraskevas KI, Veith FJ, Mikhailidis DP. Carotid intima-media thickness and ezetimibe: The end of a misunderstanding? Curr Vasc Pharmacol  2011; 9(4): 381-4.
 [http://dx.doi.org/10.2174/157016111796197198] [PMID: 21574949]

[4]
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med  2015; 372(25): 2387-97.
 [http://dx.doi.org/10.1056/NEJMoa1410489] [PMID: 26039521]

[5]
Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: A systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol  2020; 8(1): 36-49.
 [http://dx.doi.org/10.1016/S2213-8587(19)30388-2] [PMID: 31862150]

[6]
Paraskevas KI, Mikhailidis DP. More on carotid atherosclerosis and ezetimibe. Int Angiol  2017; 36(6): 580-1.
 [http://dx.doi.org/10.23736/S0392-9590.17.03892-5] [PMID: 28854780]

[7]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J  2020; 41(1): 111-88.
 [http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]

[8]
Naylor AR, Rantner B, Ancetti S, et al. European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the management of atherosclerotic carotid and vertebral artery disease. Eur J Vasc Endovasc Surg 2022; S1078-5884(22): 00237-4.
 [http://dx.doi.org/10.1016/j.ejvs.2022.04.011]

[9]
Belch JJF, Brodmann M, Baumgartner I, et al. Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. Vasa  2021; 50(6): 401-11.
 [http://dx.doi.org/10.1024/0301-1526/a000969] [PMID: 34743585]

[10]
Bonaca MP, Gutierrez JA, Cannon C, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: A secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol  2018; 6(12): 934-43.
 [http://dx.doi.org/10.1016/S2213-8587(18)30290-0] [PMID: 30396865]

[11]
Katsiki N, Mikhailidis DP. Lipids: A personal view of the past decade. Hormones (Athens)  2018; 17(4): 461-78.
 [http://dx.doi.org/10.1007/s42000-018-0058-9] [PMID: 30229482]

[12]
Benhuri B, Ueyama H, Takagi H, Briasoulis A, Kuno T. PCSK9 inhibitors and ezetimibe monotherapy in patients not receiving statins: A meta-analysis of randomized trials. Curr Vasc Pharmacol  2021; 19(4): 390-7.
 [http://dx.doi.org/10.2174/1570161118666200807114559] [PMID: 32767943]

Cite As

Current Vascular Pharmacology

Combination Therapy with Ezetimibe: An Alternative Strategy to Statin Monotherapy in the Management of Patients with Non-cardiac Vascular Disease